PURPOSE OF REVIEW: Physicians, researchers and policy makers must understand the myriad consequences of multidrug and extensively drug-resistant tuberculosis (TB) within the HIV community in order to guide clinical care, research and resource allocation. RECENT FINDINGS: Extensively drug-resistant TB can no longer be considered as occurring in isolated outbreaks as it has been reported in 45 countries from all regions of the world. HIV has been associated as an independent risk factor for infection with drug-resistant TB. HIV patients appear more likely to suffer from primary, transmitted resistance as opposed to developing acquired resistance during the course of treatment for TB. New rapid diagnostics offer promise of providing clinically useful first-line drug susceptibility information but require validation in HIV patients and smear negative individuals. Demonstration projects of community-based treatment of drug-resistant TB and integration of TB and HIV care provide opportunities to decentralize management of drug-resistant TB. SUMMARY: Multidrug-resistant and extensively drug-resistant TB disproportionately affect HIV patients and result in increased morbidity and mortality. In this study, we address these challenging issues and offer some short-term and longer term strategies for their alleviation.
PURPOSE OF REVIEW: Physicians, researchers and policy makers must understand the myriad consequences of multidrug and extensively drug-resistant tuberculosis (TB) within the HIV community in order to guide clinical care, research and resource allocation. RECENT FINDINGS: Extensively drug-resistant TB can no longer be considered as occurring in isolated outbreaks as it has been reported in 45 countries from all regions of the world. HIV has been associated as an independent risk factor for infection with drug-resistant TB. HIV patients appear more likely to suffer from primary, transmitted resistance as opposed to developing acquired resistance during the course of treatment for TB. New rapid diagnostics offer promise of providing clinically useful first-line drug susceptibility information but require validation in HIV patients and smear negative individuals. Demonstration projects of community-based treatment of drug-resistant TB and integration of TB and HIV care provide opportunities to decentralize management of drug-resistant TB. SUMMARY: Multidrug-resistant and extensively drug-resistant TB disproportionately affect HIV patients and result in increased morbidity and mortality. In this study, we address these challenging issues and offer some short-term and longer term strategies for their alleviation.
Authors: Salmaan Keshavjee; Irina Y Gelmanova; Paul E Farmer; Sergey P Mishustin; Aivar K Strelis; Yevgeny G Andreev; Alexander D Pasechnikov; Sidney Atwood; Joia S Mukherjee; Michael L Rich; Jennifer J Furin; Edward A Nardell; Jim Y Kim; Sonya S Shin Journal: Lancet Date: 2008-08-22 Impact factor: 79.321
Authors: David A J Moore; Carlton A W Evans; Robert H Gilman; Luz Caviedes; Jorge Coronel; Aldo Vivar; Eduardo Sanchez; Yvette Piñedo; Juan Carlos Saravia; Cayo Salazar; Richard Oberhelman; Maria-Graciela Hollm-Delgado; Doris LaChira; A Roderick Escombe; Jon S Friedland Journal: N Engl J Med Date: 2006-10-12 Impact factor: 91.245
Authors: Carole D Mitnick; Sonya S Shin; Kwonjune J Seung; Michael L Rich; Sidney S Atwood; Jennifer J Furin; Garrett M Fitzmaurice; Felix A Alcantara Viru; Sasha C Appleton; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Sharon Choi; Molly F Franke; Hamish S F Fraser; Dalia Guerra; Rocio M Hurtado; Darius Jazayeri; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Alexander Sloutsky; Mercedes C Becerra Journal: N Engl J Med Date: 2008-08-07 Impact factor: 91.245
Authors: Carole Mitnick; Jaime Bayona; Eda Palacios; Sonya Shin; Jennifer Furin; Felix Alcántara; Epifanio Sánchez; Madeleny Sarria; Mercedes Becerra; Mary C Smith Fawzi; Saidi Kapiga; Donna Neuberg; James H Maguire; Jim Yong Kim; Paul Farmer Journal: N Engl J Med Date: 2003-01-09 Impact factor: 91.245
Authors: David Coetzee; Katherine Hilderbrand; Eric Goemaere; Francine Matthys; Marleen Boelaert Journal: Trop Med Int Health Date: 2004-06 Impact factor: 2.622
Authors: A Roderick Escombe; Clarissa C Oeser; Robert H Gilman; Marcos Navincopa; Eduardo Ticona; William Pan; Carlos Martínez; Jesus Chacaltana; Richard Rodríguez; David A J Moore; Jon S Friedland; Carlton A Evans Journal: PLoS Med Date: 2007-02 Impact factor: 11.069
Authors: Stellah G Mpagama; Norah Ndusilo; Suzanne Stroup; Happiness Kumburu; Charles A Peloquin; Jean Gratz; Eric R Houpt; Gibson S Kibiki; Scott K Heysell Journal: Antimicrob Agents Chemother Date: 2013-11-18 Impact factor: 5.191
Authors: T A Thomas; S V Shenoi; S K Heysell; F J Eksteen; V B Sunkari; N R Gandhi; G Friedland; N S Shah Journal: Int J Tuberc Lung Dis Date: 2010-10 Impact factor: 2.373
Authors: Elinore F McCance-Katz; David E Moody; Sudha Prathikanti; Gerald Friedland; Petrie M Rainey Journal: Drug Alcohol Depend Date: 2011-05-19 Impact factor: 4.492
Authors: Max D Driscoll; Kirsty J McLean; Colin Levy; Natalia Mast; Irina A Pikuleva; Pierre Lafite; Stephen E J Rigby; David Leys; Andrew W Munro Journal: J Biol Chem Date: 2010-09-30 Impact factor: 5.157
Authors: Hind Satti; Megan M McLaughlin; Bethany Hedt-Gauthier; Sidney S Atwood; David B Omotayo; Likhapha Ntlamelle; Kwonjune J Seung Journal: PLoS One Date: 2012-10-24 Impact factor: 3.240
Authors: Stellah G Mpagama; Scott K Heysell; Nora D Ndusilo; Happiness H Kumburu; Isack A Lekule; Riziki M Kisonga; Jean Gratz; Martin J Boeree; Eric R Houpt; Gibson S Kibiki Journal: PLoS One Date: 2013-05-13 Impact factor: 3.240